Download presentation
Presentation is loading. Please wait.
Published byMorris Bertram Barrett Modified over 6 years ago
1
Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB (HER2-Positive) and CALGB (Triple-Negative) David W. Ollila, MD, FACS, Constance T. Cirrincione, MS, Donald A. Berry, PhD, Lisa A. Carey, MD, William M. Sikov, MD, Clifford A. Hudis, MD, Eric P. Winer, MD, Mehra Golshan, MD, FACS Journal of the American College of Surgeons Volume 224, Issue 4, Pages (April 2017) DOI: /j.jamcollsurg Copyright © 2017 American College of Surgeons Terms and Conditions
2
Figure 1 C40601 schema. AC, adjuvant chemotherapy; BCT, breast-conserving therapy; HER2, human epidermal growth factor receptor-2; T, weekly paclitaxel; H, trastuzumab; L, lapatinib. ∗Excluding clinical T4d tumors. Journal of the American College of Surgeons , DOI: ( /j.jamcollsurg ) Copyright © 2017 American College of Surgeons Terms and Conditions
3
Figure 2 C40603 Schema. AUC, area under the curve; BCT, breast-conserving therapy; ddAC, dose-dense doxorubicin and cyclophosphamide. ∗Treatment decision made at the discretion of breast oncology team. Journal of the American College of Surgeons , DOI: ( /j.jamcollsurg ) Copyright © 2017 American College of Surgeons Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com Inc.
All rights reserved.